ZYBERNO
Stock Report
Updated Aug 21, 2026

Turn Therapeutics Inc. (TTRX)

Healthcare • NASDAQ

$9.46

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
5.0/100
POOR BUSINESS
Turn Therapeutics Inc. (TTRX) scores 5/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (0.0%)
Debt-to-Equity (Solvency Risk):CRITICAL (10.26x)
Operating Margin (Operational Efficiency):CRITICAL (0.0%)
Return on Capital (Capital Efficiency):CRITICAL (-62.7%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

Turn Therapeutics Inc. (TTRX) stock report — Zyberno Score 5/100 (POOR BUSINESS). Full financial analysis on Zyberno.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:9.46
Market Cap:$281.79M

Valuation Multiples (2)

P/B Ratio:410.25x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$279.21M

Price Action & Momentum (1)

% of 52-Week High:35.7%
B. Profitability Assessment

Return Metrics (3)

Reinvestment Rate:1.2%
Fundamental Growth Rate (g):-0.8%

Margin Analysis (1)

Ebitda Margin:0.0%

Yield Metrics (2)

Earnings Yield:-$999.00
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:1.19x
Quick Ratio:1.19x
Cash Ratio:1.14x

Leverage Analysis (3)

Debt To Equity Ttm:10.26x
Debt-to-Equity Ratio:10.26x
Debt To Ebitda:-999.00x

Coverage Ratios (1)

Times Interest Earned:-999.00

Capital Structure (4)

Working Capital:1,664,087.00
Cash And Cash Equivalents:9,948,952.00
Long Term Debt:$6.06M
Net Debt:-$2.59M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

$0.00
Cost Of Revenue Ttm:$0.00

Profitability Breakdown (2)

$0.00-$5.86M

Bottom Line Performance (3)

-$3.19M
Income Before Tax:$0.00
Ebitda Ttm:-5,805,902.00

Operating Expenses (5)

Operating Expenses:1,628,060.00
R And D Expense:475,064.00
Sga Expense:1,152,996.00
Income Tax Expense:$0.00
Interest Expense:0.00

Expense Ratios (1)

Ebitda Margin:0.0%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$16.96M
Current Assets:$10.43M
Ppe Net:0.00
Goodwill:0.00
Intangible Assets:$911.22K

Liability Structure (4)

Total Liabilities:16,273,831.00
Current Liabilities:8,764,111.00
Long Term Debt:$6.06M
Short Term Debt:$1.30M

Equity & Capital (3)

Equity:$686.89K
Retained Earnings:-$29.21M
Common Stock:500,000,000.00

Working Capital Items (3)

Accounts Receivable:0.00
Inventory:0.00
Accounts Payable:0.00

Special Items (2)

Contract Liabilities:1,438,013.00
Stock Based Compensation:280,830.00
C. Cash Flow Analysis

Operating Activities (2)

-$2.56M$0.00

Investment Activities (1)

Investing Cash Flow:-$12.23K

Financing Activities (3)

Financing Cash Flow:$7.79M
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:998,092.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (1)

Earnings Per Share Ttm:-$0.11

Revenue & Cash Per Share (1)

Operating Cash Flow Per Share:-$0.09

Book Value & Capital (2)

Book Value Per Share:$0.02
Cash Per Share:0.33

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (1)

Working Capital Turnover Ttm:-999.00x

Receivables Management (2)

Receivables Turnover Ttm:-999.00x
Days Sales Outstanding Ttm:-999.00

Inventory Management (2)

Inventory Turnover Ttm:-999.00x
Days Inventory Outstanding Ttm:-999.00

Payables & Cash Cycle (2)

Days Payable Outstanding:-999.00
Cash Conversion Cycle:-999.00
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:20.00
Quality Score:10.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Damodaran Growth Analysis (2)

Reinvestment Rate:1.2%
Fundamental Growth Rate (g):-0.8%
B. Log-Linear Regression Growth Analysis
C. Company Profile & Context

Corporate Information (6)

Symbol:TTRX
Company Name:Turn Therapeutics Inc.
Sector:Healthcare
Industry:Pharmaceuticals
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:low
Volume Category:N/A

Share Structure (3)

Shares Outstanding:29.79M
Shares Outstanding Basic:29.79M
Shares Outstanding Diluted:29.79M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-08-21 20:33:16 UTC
Data Timestamp:2026-08-19T05:59:23.392697
Scroll to Top